RT Journal Article
SR Electronic
T1 Using one–to–many urine proteome comparisons to provide clues for fever of unknown origin
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.23.21264016
DO 10.1101/2021.09.23.21264016
A1 Zhao, Chenyang
A1 Wei, Lilong
A1 Wei, Jing
A1 Gao, Youhe
YR 2021
UL http://medrxiv.org/content/early/2021/09/24/2021.09.23.21264016.abstract
AB Objective To provide diagnostic evidence and clues for patients with fever of unknown origin (FUO) through urine proteomics analysis.Methods Urine samples of FUO were one–to–many analysed by using liquid chromatography tandem mass spectrometry(LC–MS/MS) to identify differential proteins and related biological pathways. One–to–many analysis means a comparative analysis of one sample to many controls.Results We observed biological pathways related to fever, such as LXR/RXR activation, FXR/RXR activation and acute phase response signaling, etc., which indicates that urine can obviously distinguish disease from health status. In addition, we found that the results of each sample were different, which highlight the necessity of one–to–many analysis.Conclusions The combined method of urine proteomics and one–to–many analysis can provide clues for FUO, and might also be applied to the exploration of any unknown disease.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis experiment was based on the reuse of discarded samples from Laboratory Medicine, and the process did not involve any patient identity informationFunding StatementThis work was supported by the National Key Research and Development Program of China (2018YFC0910202 and2 016YFC1306300); the Fundamental Research Funds for the Central Universities (2020KJZX002); the Beijing Natural Science Foundation (7172076); the Beijing Cooperative Construction Project (110651103); the Beijing Normal University (11100704). Key Clinical Specialty Project of Beijing (2020)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants signed informed consent forms, and the study received ethical approval from China-Japan Friendship Hospital (No. 2019-42-K30).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data referred to in the manuscript are availability.